Media Library
Presentations From World ADC Asia 2019
Antibody-drug Conjugates Derived from Cytotoxic Seco-CBI-dimer Payloads are Highly Efficacious in Xenograft Models & Form Protein Adducts in Vivo
By Dian Su, Genentech
Site-Specific Conjugation & Next-Generation ADCs
By Bruce Han, NewBio Therapeutics
Development of Series Innovative ADCs Targeting Solid Tumors
By Xiaomai Zhou, DAC Biotech
Check out our speaker interview with Tse-Wen Chang to learn everything from the biggest ADC challenges faced in Asia to first-hand insight on Tse-Wen’s work
ADCs: Requirements in terms of GMP and occupational safety
A BCMA-Targeting Antibody-Drug Conjugate with NTERM Conjugation for Treating Multiple Myeloma
Jinwon Jung
ADCs with high ADR, high targeting valence, and product homogeneity
Tse Wen Chang, Ph.D. CEO, Immunwork, Inc.
Development of Innovative ADCs Targeting Solid Tumors
Xiaomai Zhou
World ADC Asia Infographic
Clinical Development of ADC-IO Combinations: Today and Tomorrow
Jay Harper, Ph.D., MedImmune Oncology Research
Antibody Drug Conjugates: Process Development and Analytical Considerations
Michael Hay – Bristol-Myers Squibb
Immunogenicity Assay Strategies for Antibody-Drug Conjugates
Seema Kumar, PhD, EMD Serono Research & Development Institute
